Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN).
CEO Fred Aslan told the Clinical Trials Arena that the company is currently enrolling patients on the trial with hopes to dose the first patient within H1 2024.
Read the full article here.
[excerpt] The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren’t the only option for cell therapy. Promising work is being done with natural killer, or NK cells, a different kind of immune system cell that could work even better in some ways....
Chris Horan, chief technical operations officer, Artiva Biotherapeutics discusses with Cell & Gene natural killer (NK) cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK. He answers the following questions: Why do NK cell therapies hold promise in treating autoimmune disease? What is the biggest technical/scientific challenge of developing NK-based therapies, and what...
Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies. Watch the interview here.